{"prompt": "['OSTPDL1', 'Page 6 of 60', 'Various immunomonitoring assays were incorporated into the in vivo', 'studies. Treatment with avelumab resulted in a consistent increase in the', 'percentage of CD8+PD-1+ T cells and an increased frequency of CD8+ T', 'cells with an effector memory (TEM) phenotype as determined by flow', 'cytometry. These changes correlated with anti-tumor effect. Increases in', 'tumor antigen-specific T cell responses, as measured by enzyme-linked', 'immunosorbent spot and pentamer immunoassays, were evident', 'following treatment with avelumab. These responses were enhanced', 'when combined with FOLFOX or radiation. This has led to speculation', 'that increases in CD8+PD-1+ T cells, CD8+ TEM cells, and antigen-', 'specific T cell responses may be leveraged as pharmacodynamic', 'biomarkers with translational relevance to the clinical setting', '2.2.3 Preclinical Pharmacokinetic Studies', 'Avelumab demonstrated pronounced non-linear pharmacokinetic (PK)', 'characteristics in mice and monkeys in single dose studies at doses', 'below 20 mg/kg, suggesting a combination of first order catabolic', 'clearance and saturable target-mediated clearance. Toxicokinetic data', 'from repeated dose toxicity studies in mice, rats and monkeys indicated', 'that the PK of avelumab was linear within the dose range of 20 to', '140mg/kg, suggesting that the target mediated clearance could be', 'saturated when higher doses are administered. Similar terminal half-lives', 'of approximately 60 to 70 hours were observed in toxicity studies in mice', 'and monkeys. A PK/pharmacodynamic (PD) study in C57BL/6 mice was', 'used to correlate receptor occupancy data of avelumab in blood with drug', 'combinations. A plasma concentration of 58.5 g/mL was calculated as', 'required for 95% target occupancy in this model.', 'Avelumab is immunogenic in mice, rats, and monkeys with a lower', 'incidence of anti-drug antibodies (ADAs) at higher doses. The latter is', 'probably due to interference of free avelumab with the immunogenicity', 'assay (drug interference). In animals, the generated ADAs seem to have', 'the potential to increase the clearance of the avelumab. As the fully', 'human avelumab represents a foreign protein to the immune system of', 'animals, the observed immunogenicity of avelumab in rodents and non-', 'human primates is not deemed predictive for an immune response to', 'avelumab in humans.', '2.2.4 Preclinical Toxicology Studies', 'The toxicological profile of avelumab was evaluated in repeat-dose', 'toxicity studies of 4-week duration with once weekly IV bolus', 'injection/infusion of avelumab in mice, rats, and cynomolgus monkeys. A', 'repeat-dose toxicity study with intermittent once weekly IV infusion of', 'avelumab over 13 weeks followed by an 8-week recovery period in', 'cynomolgus monkeys was also conducted. In addition, in vitro cytokine', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-20 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 7 of 60', 'release assays (CRA) in human and cynomolgus monkey whole blood and', 'peripheral blood mononuclear cells (PBMCs) followed by an optimized', 'CRA in phyto-hemagglutinin (PHA) pre-stimulated PBMCs from 16 human', 'volunteers was completed. Tissue cross reactivity (TCR) studies in normal', 'human and cynomolgus monkey tissues have also been performed.', 'On the basis of the binding affinity data, the cynomolgus monkey and the', 'mouse were selected as relevant species for the nonclinical safety testing', 'of avelumab. Due to severe hypersensitivity reactions after repeated', 'administration of avelumab in mice and the low binding affinity in rats,', 'rodent species are not considered appropriate for nonclinical safety', 'testing of avelumab and therefore, a single species approach', '(cynomolgus monkey only) is applied.', 'In cynomolgus monkeys, clinical signs of hypersensitivity have not been', 'seen after repeated treatment with avelumab at dose levels of 20, 60, and', '140 mg/kg, respectively, in either the pilot 4-week study or in the pivotal', '13-week IV repeat-dose toxicity study. For both studies, a no observed', 'adverse effect level (NOAEL) of 140 mg/kg for systemic toxicity was', 'established.', 'Initial cytokine release assays in human and cynomolgus monkey whole', 'blood and PBMCs revealed no clear-cut evidence for release of pro-', 'inflammatory cytokines. However, a subsequent, optimized CRA', 'demonstrated evidence of potential cytokine release in PHA pre-', 'stimulated PBMCs. However, clinical experience has demonstrated that', 'the relative risk of an infusion reaction is low (approximately 2%) and with', 'pre-medication, the incidence of infusion reaction drops to less than 1%,', 'indicating that the optimized CRA overestimates the risk of cytokine', 'release in the clinical setting.', '2.3', 'Clinical Studies', '2.3.1 Adult Studies', 'Clinical data regarding pharmacokinetics and safety for avelumab is', 'available from four ongoing clinical trials for the treatment of adult', 'metastatic or locally advanced solid tumors, across Phases I, II (EMR', '100070-003), and III. EMR 100070-001 is a Phase I open label multiple', 'ascending dose trial with two parts: a dose escalation cohort with a 3+3', 'enrollment design to determine the maximum tolerated dose (MTD) of', 'avelumab with dose levels of 1, 3, 10 and 20 mg/kg every 2 weeks, and', 'an expansion cohort for 16 different tumor subtypes. EMR 100070-002', 'is a Phase I trial to investigate the tolerability, safety, pharmacokinetics', '(PKs), biological and clinical activity of avelumab in Japanese patients with', 'metastatic or locally advanced solid tumors with an expansion cohort for', 'Asian patients with gastric cancer, and was conducted in a similar dose', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}